Literature DB >> 29932283

Therapeutic response of metastatic angiomatoid fibrous histiocytoma carrying EWSR1-CREB1 fusion to the interleukin-6 receptor antibody tocilizumab.

Samara L Potter1, Norma M Quintanilla2, Danielle K Johnston1, Bindi Naik-Mathuria3, Rajkumar Venkatramani1.   

Abstract

Angiomatoid fibrous histiocytoma (AFH) is a rare soft tissue tumor that has been associated with EWSR1-CREB1 gene fusion. Outcome in patients with unresectable distant metastases is generally fatal. Interleukin-6 (IL-6) secretion has been described in tumors with EWSR1-CREB1 fusion, and may promote tumor growth due to autocrine stimulation. Tocilizumab is an IL-6 receptor antibody that has potential benefit as a targeted therapy in refractory neoplasms with IL-6 secretion. We describe a child with metastatic AFH with EWSR1-CREB1 fusion and elevated IL-6 whose disease progressed during treatment with traditional chemotherapeutic agents, but improved after targeted therapy with tocilizumab.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  EWSR1-CREB1; IL-6 receptor antibody; angiomatoid fibrous histiocytoma; interleukin-6; tocilizumab

Mesh：

Substances：

Year:  2018        PMID： 29932283     DOI： 10.1002/pbc.27291

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


  6 in total

1.  Intracranial angiomatoid fibrous histiocytoma with rhabdoid features: a mimic of rhabdoid meningioma.

Authors:  M Adelita Vizcaino; Caterina Giannini; Howard T Chang; Benjamin R Kipp; Karen Fritchie; Rachael Vaubel
Journal:  Brain Tumor Pathol       Date:  2021-01-12       Impact factor: 3.298

2.  PD-L1 expression in angiomatoid fibrous histiocytoma.

Authors:  Joshua Byers; Hong Yin; Heather Rytting; Suzanna Logan; Mai He; Zhongxin Yu; Dehua Wang; Mikako Warren; Shamlal Mangray; Louis P Dehner; Shengmei Zhou
Journal:  Sci Rep       Date:  2021-01-26       Impact factor: 4.379

3.  Tocilizumab Controls Paraneoplastic Inflammatory Syndrome but Does Not Suppress Tumor Growth of Angiomatoid Fibrous Histiocytoma.

Authors:  Hideaki Sabe; Akitomo Inoue; Shigenori Nagata; Yoshinori Imura; Toru Wakamatsu; Satoshi Takenaka; Hironari Tamiya
Journal:  Case Rep Oncol Med       Date:  2021-06-16

4.  Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma.

Authors:  Lauriane Eberst; Philippe A Cassier; Mehdi Brahmi; Franck Tirode; Jean-Yves Blay
Journal:  ESMO Open       Date:  2020-06

Review 5.  The spectrum of rare central nervous system (CNS) tumors with EWSR1-non-ETS fusions: experience from three pediatric institutions with review of the literature.

Authors:  Oscar Lopez-Nunez; Barbara Cafferata; Mariarita Santi; Sarangarajan Ranganathan; Thomas M Pearce; Scott M Kulich; Kelly M Bailey; Alberto Broniscer; Sabrina Rossi; Angelica Zin; MacLean P Nasrallah; Marilyn M Li; Yiming Zhong; Evelina Miele; Rita Alaggio; Lea F Surrey
Journal:  Brain Pathol       Date:  2020-11-06       Impact factor: 6.508

6.  An integrative histopathological and epigenetic characterization of primary intracranial mesenchymal tumors, FET:CREB-fused broadening the spectrum of tumor entities in comparison with their soft tissue counterparts.

Authors:  Arnault Tauziède-Espariat; Philipp Sievers; Frédérique Larousserie; Joseph Benzakoun; Delphine Guillemot; Gaëlle Pierron; Mathilde Duchesne; Emmanuelle Uro-Coste; Alexandre Roux; Alexandre Vasiljevic; Tanguy Fenouil; David Meyronet; Karima Mokhtari; Marc Polivka; Audrey Rousseau; Frédérique Bost-Bezeaud; Samir Akoury; Johan Pallud; Chiara Benevello; Lauren Hasty; Albane Gareton; Emmanuèle Lechapt; Fabrice Chrétien; Thomas Blauwblomme; Kévin Beccaria; Stéphanie Puget; Felix Sahm; Pascale Varlet
Journal:  Brain Pathol       Date:  2021-07-27       Impact factor: 6.508
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.